Factors associated with noncompletion of latent tuberculosis infection treatment: Experience from the PREVENT TB trial in the United States and Canada

Clinical Infectious Diseases

Volumn 62, Issue 11, 2016, Pages 1390-1400

  Moro, Ruth N ^a,b   Borisov, Andrey S ^a   Saukkonen, Jussi ^c   Khan, Awal ^a   Sterling, Timothy R ^d   Villarino, M Elsa ^a   Scott, Nigel A ^a,b   Shang, Nong ^a   Kerrigan, Amy ^d   Goldberg, Stefan V ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CDC FOUNDATION   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

medication adherence; patient compliance; treatment completion

Indexed keywords

ALCOHOL; ISONIAZID; RIFAPENTINE; TUBERCULOSTATIC AGENT;

ADULT; ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ARTICLE; CANADA; DIRECTLY OBSERVED THERAPY; ETHNICITY; FEMALE; FLU LIKE SYNDROME; HUMAN; INTRAVENOUS DRUG ABUSE; LATENT TUBERCULOSIS; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; PRISON; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SMOKING; TREATMENT REFUSAL; UNITED STATES; CONTROLLED STUDY; MEDICATION COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA;

ADULT; ANTITUBERCULAR AGENTS; CANADA; FEMALE; HUMANS; LATENT TUBERCULOSIS; MALE; MEDICATION ADHERENCE; UNITED STATES;

EID: 84971569610     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw126     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention (CDC). Controlling tuberculosis in the United States: recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recommen Rep 2005; 54(No.RR-12):1-69.
2. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999; 3:847-50.
3. International Union Against Tuberculosis (IUAT). Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982; 60:555-64.
4. Horsburgh CR Jr, Goldberg S, Bethel J, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010; 137:401-9.
5. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006; 130:1712-7.
6. Page KR, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006; 166:1863-70.
7. Goldberg S, Wallace J, Jackson JC, Chaulk CP, Nolan CM. Cultural case management of latent tuberculosis infection. Int J Tuberc Lung Dis 2004; 8:76-82.
8. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365:2155-66.
9. Obrien CP. The CAGE questionnaire for detection of alcoholism. JAMA 2008; 300:2054.
10. McCulloch CE, Searle SR. Generalized, linear, and mixed models. New York: John Wiley & Sons; 2001.
11. Menzies D, Dion MJ, Francis D, et al. In closely monitored patients, adherence in the first month predicts completion of therapy for latent tuberculosis infection. Int J Tuberc Lung Dis 2005; 9:1343-8.
12. Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-Analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 2009; 49:1883-9.
13. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-Analysis. Clin Infect Dis 2005; 40:670-6.
14. Menzies D, Dion M, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170:445-9.
15. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008; 149:689-97.
16. Fiske CT, Yan FX, Hirsch-Moverman Y, Sterling TR, Reichler MR. Risk factors for treatment default in close contacts with latent tuberculous infection. Int J Tuberc Lung Dis 2014; 18:421-7.
17. López G, Wood M, Ayesta FJ. 10 years of innovation in the treatment of latent tuberculosis infection: a comparison between standard and short course therapies in directly observed therapy [Spanish]. Rev Esp Sanid Peni 2011; 13:3-14.
18. Parsyan AE, Saukkonen J, Barry MA, Sharnprapai S, Horsburgh Jr. C.R. Predictors of failure to complete treatment for latent tuberculosis infection. J Infect 2007; 54:262-6.
19. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Resp Crit Care 2003; 168:443-7.
20. Shieh FK, Snyder G, Horsburgh CR, Bernardo J, Murphy C, Saukkonen J. Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Resp Crit Care 2006; 174:717-21.
21. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 2008; 12:1235-54.
22. Chan ED, Kinney WH, Honda JR, et al. Tobacco exposure and susceptibility to tuberculosis: is there a smoking gun? Tuberculosis 2014; 94:544-50.
23. Gust DA, Mosimaneotsile B, Mathebula U, et al. Risk factors for non-Adherence and loss to follow-up in a three-year clinical trial in Botswana. PLoS One 2011; 6:e18435.
24. Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Int J Tuberc Lung Dis 2010; 14:551-9.
25. Hirsch-Moverman Y, Bethel J, Colson PW, Franks J, El-Sadr W. Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience. Int J Tuberc Lung Dis 2010; 14:1104-11.
26. White MC, Tulsky JP, Goldenson J, Portillo CJ, Kawamura M, Menendez E. Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail. Arch Intern Med 2002; 162:1044-50.
27. Nolan CM, Roll L, Goldberg SV, Elarth AM. Directly observed isoniazid preventive therapy for released jail inmates. Am J Resp Crit Care 1997; 155:583-6.
28. Centers for Disease Control and Prevention. Prevention and control of tuberculosis in correctional and detention facilities: recommendations from CDC. Endorsed by the Advisory Council for the Elimination of Tuberculosis, the National Commission on Correctional Health Care, and the American Correctional Association. MMWR Recommen Rep 2006; 55(No. RR-9):1-44.
29. Federal Bureau of Prisons (FBO). Clinical Practice Guideline 2014.Washington, DC: FOB; 2014. Available at: http://www.bop.gov/resources/pdfs/latent-TB-infection.pdf. Accessed 21 March 2016.
30. Besch CL. Compliance in clinical trials. AIDS (London, England) 1995; 9:1-10.
31. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-97.
32. Hirsch-Moverman Y, Shrestha-Kuwahara R, Bethel J, et al. Latent tuberculous infection in the United States and Canada: who completes treatment and why? Int J Tuberc Lung Dis 2015; 19:31-38.